Tin tức & Cập nhật

Leaving out the use of external beam parametrial boost (EBPB) for locally advanced cervical cancer does not seem to negatively affect local control or survival in the era of image-guided brachytherapy, results of a study have shown. This then supports a reduced need for standardized use of parametrial boost.

In individuals receiving disease-modifying antirheumatic drugs* (DMARDs) for inflammatory rheumatic diseases** (IRD), humoral response remained satisfactory following administration of the second dose of the Pfizer mRNA vaccine against SARS-CoV-2, a study suggests.

Hepatic arterial infusion chemotherapy (HAIC) with fluorouracil, leucovorin and oxaliplatin (FOLFOX) as first-line treatment significantly improves overall survival (OS) vs transarterial chemoembolization (TACE) in patients with large, unresectable hepatocellular carcinoma (HCC), a phase III trial in China has shown.

Some patients with irritable bowel syndrome (IBS) may achieve symptom reduction, particularly diarrhoea, on a gluten-free diet, and who these patients are may be identified by using the antigliadin immunoglobulin G (IgG) as a biomarker, according to a study.

Among healthy individuals, a fasting plasma glucose (FPG) concentration within the range of 90–99 mg/dL increases the risk of type 2 diabetes, a new Japan study has found.

Intravitreal bevacizumab (IVB) injections induce short-lived visual benefit but ease the need for vitrectomy in proliferative diabetic retinopathy (PDR) patients with vitreous haemorrhage (VH) who had undergone prior complete panretinal photocoagulation (PRP), a recent study has found.

Among patients with type 2 diabetes (T2D), women appear to be at greater risk of accelerated cognitive decline than men, as reported in a study. This risk increase can be partly explained by depressive symptoms being greater among women.

Pembrolizumab extended recurrence-free survival (RFS) in patients with high-risk stage II melanoma who had undergone complete resection, interim analysis results of the phase III KEYNOTE-716 trial showed.